Intravenous Iron Infusion on Chemotherapy-induced Anemia
Status:
Not yet recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
FOLFOX, the first-line regimen based on 5-FU and oxaliplatin, is adjuvant chemotherapy for
pathologic stage II/III colorectal cancer patients. Among various side effects of FOLFOX,
chemotherapy-induced anemia occurs in about 30% of patients with FOLFOX chemotherapy. An oral
iron supplement is a widely accepted treatment for chemotherapy-induced anemia, but an oral
iron supplement has a lot of inconveniences that can make patients' adherence worse, such as
gastrointestinal discomfort, a long period of oral intake, and late recovery of serum iron
level.
Intravenous iron infusion has been recently reported to be effective and safe to correct
anemia. Previous studies reported that intravenous iron is also effective to correct
chemotherapy-induced anemia. However, there is a paucity of studies associated with
colorectal cancer patients with FOLFOX chemotherapy.
This study aimed to evaluate the effect of intravenous iron on chemotherapy-induced anemia
after FOLFOX chemotherapy for patients with colorectal cancer compared with the effect of
oral iron supplements. Parameters including serum Hb, serum iron, serum ferritin
concentrations, total iron-binding capacity, absolute neutrophil count, platelet, albumin, C
reactive protein, hepcidin, soluble transferrin receptor, and IL6 will be analyzed. In
addition, information on chemotoxicity, adverse events during chemotherapy and quality of
life will be collected and analyzed.